AN2 Therapeutics Inc. (ANTX)
ANTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ANTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001880438 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $20.2M cash; operating cash flow -$7.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 37,943,650 (2026-11-05); 27,402,024 a year earlier; 29,741,445 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-04-20 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, San Jose, California, United States | PCAOB Form AP 2026-03-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $12K, sold $395K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$8.0M | -$6.1M | $20.2M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$8.2M | -$7.0M | $44.3M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$10.0M | -$12.1M | $53.5M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | Not filed | -$8.7M | -$5.2M | $19.9M | No debt tags | Needs four quarters | 10-K 2026-03-17 |
| Q3 2025 2025-09-30 | Not filed | -$9.4M | -$6.4M | $18.0M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | Not filed | -$6.5M | -$7.6M | $18.2M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2025 2025-03-31 | Not filed | -$10.6M | -$10.6M | $20.0M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2024 2024-12-31 | Not filed | -$7.5M | -$5.3M | $21.4M | No debt tags | Needs four quarters | 10-K 2026-03-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-04-20 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 390 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +13.7% |
| 1 month | +26.4% |
| 3 months | -23.9% |
| Year to date | +299.1% |
| 1 year | +302.7% |
| From 52-week high | -27.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ORMP | Oramed Pharmaceuticals Inc. | $3.90 | +5.12% | $169.6M |
| PYXS | Pyxis Oncology Inc. | $1.41 | -10.76% | $168.6M |
| PRQR | ProQR Therapeutics N.V. | $1.18 | -16.31% | $166.5M |
| ELDN | Eledon Pharmaceuticals Inc. | $1.97 | -6.86% | $166.4M |
| IFRX | InflaRx N.V. | $1.18 | +0.85% | $173.9M |
| KRRO | Korro Bio Inc. | $12.71 | -6.61% | $174.5M |
| WHWK | Whitehawk Therapeutics Inc. | $3.01 | -1.63% | $177.6M |
| SLGL | Sol-Gel Technologies Ltd. | $54.96 | -0.29% | $179.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier